Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Trial ID or NCT#

NCT00349830

Status

recruiting iconRECRUITING

Purpose

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Official Title

Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes

Investigator(s)

Quynh-Thu Le, MD
Quynh-Thu Le, MD
Radiation oncologist
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Daniel Chang
Elizabeth Kidd
Elizabeth Kidd
Radiation oncologist
Associate Professor of Radiation Oncology (Radiation Therapy)
Maximilian Diehn, MD, PhD
Maximilian Diehn, MD, PhD
Radiation oncologist
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Anson Lowe
Billy W Loo, Jr, MD PhD FASTRO FACR
Billy W Loo, Jr, MD PhD FASTRO FACR
Radiation oncologist, Thoracic specialist
Professor of Radiation Oncology (Radiation Therapy)

Contact us to find out if this trial is right for you.

Contact

Rene Bonilla
650-498-7703